BEAM news

Latest 1 stories · newest Aug 4, 2026

BEAM

Beam Doses First Patient in BEAM-302 Global Pivotal Trial; Reports Q1

Beam Therapeutics dosed the first patient in the global pivotal cohort of its BEAM-302 trial for AATD and reported $1.2 billion in cash, indicating continued clinical progress and operational strength.

Earnings Aug 4, 2026 sentiment +0.30 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same BEAM feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/BEAM/newsSTART FREE